Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA damage

被引:36
作者
Barker, CR
McNamara, AV
Rackstraw, SA
Nelson, DE
White, MR
Watson, AJM
Jenkins, JR [1 ]
机构
[1] Univ Liverpool, Dept Med, Henry Wellcome Lab Mol & Cellular Gastroenterol, Sch Clin Sci,Div Gastroenterol, Liverpool L69 3BX, Merseyside, England
[2] Univ Liverpool, Sch Biol Sci, Ctr Cell Imaging, Liverpool L69 7ZB, Merseyside, England
关键词
D O I
10.1093/nar/gkj516
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Topoisomerase II plays a crucial role during chromosome condensation and segregation in mitosis and meiosis and is a highly attractive target for chemotherapeutic agents. We have identified previously topoisomerase II and heat shock protein 90 (Hsp90) as part of a complex. In this paper we demonstrate that drug combinations targeting these two enzymes cause a synergistic increase in apoptosis. The objective of our study was to identify the mode of cell killing and the mechanism behind the increase in topoisomerase II mediated DNA damage. Importantly we demonstrate that Hsp90 inhibition results in an increased topoiosmerase II activity but not degradation of topoisomerase II and it is this, in the presence of a topoisomerase II poison that causes the increase in cell death. Our results suggest a novel mechanism of action where the inhibition of Hsp90 disrupts the Hsp90-topoisomerase II interaction leading to an increase in and activation of unbound topoisomerase II, which, in the presence of a topoisomerase II poison leads to the formation of an increased number of cleavable complexes ultimately resulting in rise in DNA damage and a subsequent increase cell death.
引用
收藏
页码:1148 / 1157
页数:10
相关论文
共 26 条
[1]   Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress [J].
Arlander, SJH ;
Eapen, AK ;
Vroman, BT ;
McDonald, RJ ;
Toft, DO ;
Karnitz, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) :52572-52577
[2]  
BARKER CR, 2006, IN PRESS INT J CANC
[3]   Hsp90: an emerging target for breast cancer therapy [J].
Beliakoff, J ;
Whitesell, L .
ANTI-CANCER DRUGS, 2004, 15 (07) :651-662
[4]   The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy [J].
Blagosklonny, MV ;
Fojo, T ;
Bhalla, KN ;
Kim, JS ;
Trepel, JB ;
Figg, WD ;
Rivera, Y ;
Neckers, LM .
LEUKEMIA, 2001, 15 (10) :1537-1543
[5]   UNUSUAL EXPRESSION AND LOCALIZATION OF HEAT-SHOCK PROTEINS IN HUMAN TUMOR-CELLS [J].
FERRARINI, M ;
HELTAI, S ;
ZOCCHI, MR ;
RUGARLI, C .
INTERNATIONAL JOURNAL OF CANCER, 1992, 51 (04) :613-619
[6]   The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons [J].
Flatten, K ;
Dai, NT ;
Vroman, BT ;
Loegering, D ;
Erlichman, C ;
Karnitz, LM ;
Kaufmann, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (14) :14349-14355
[7]   Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice [J].
Fortune, JM ;
Osheroff, N .
PROGRESS IN NUCLEIC ACID RESEARCH AND MOLECULAR BIOLOGY, VOL 64, 2000, 64 :221-253
[8]   The Hsp90 chaperone complex as a novel target for cancer therapy [J].
Goetz, MP ;
Toft, DO ;
Ames, MM ;
Erlichman, C .
ANNALS OF ONCOLOGY, 2003, 14 (08) :1169-1176
[9]   The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint [J].
Ho, CC ;
Siu, WY ;
Chow, JPH ;
Lau, A ;
Arooz, T ;
Tong, HY ;
Ng, IOL ;
Poon, RYC .
EXPERIMENTAL CELL RESEARCH, 2005, 304 (01) :1-15
[10]   HSF-1 interacts with Ral-binding protein 1 in a stress-responsive, multiprotein complex with HSP90 in vivo [J].
Hu, YZ ;
Mivechi, NF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (19) :17299-17306